Physician perceptions to use of trastuzumab in HER2+breast cancer in India

被引：0
|
作者：
Ramanjinappa, N. [1 ]
Agarwal, J. [1 ]
Upveja, K. H. [1 ]
机构：
[1] Viatris, Dept Med Affairs, Bengaluru, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页码：S1437 / S1437
页数：1
相关论文
共 50 条
  • [1] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    [J]. ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
  • [3] Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+breast cancer
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    van der Wall, Elsken
    van Diest, Paul J.
    Hauptmann, Michael
    Siesling, Sabine
    Sonke, Gabe S.
    Linn, Sabine C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 817 - 830
  • [4] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [5] Barriers to the use of trastuzumab for HER2+breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets.
    Lammers, Philip Edward
    Criscitiello, Carmen
    Curigliano, Giuseppe
    Jacobs, Ira Allen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [7] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
    Luis, Ines Vaz
    Lin, Nancy U.
    Keating, Nancy Lynn
    Barry, William Thomas
    Lii, Joyce
    Burstein, Harold J.
    Winer, Eric P.
    Freedman, Rachel A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [9] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
    Miller, K. D.
    Steding, C. E.
    Prasad, N.
    Rojas, L. A.
    Herbert, B-S
    [J]. CANCER RESEARCH, 2012, 72
  • [10] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345